Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NDEPTH: Hydroxyurea Dose Prediction in Sickle Cell Disease
NCT02042222Phase 1Completed
- Sponsor
- Baylor College of Medicine
- Start
- Oct 2013
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of hydroxyurea in sickle cell disease (SCD) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Time to patients reaching the maximum tolerated dose (MTD) of the medication at 6 months. Started Oct 2013; status: completed.
02
Drugs
hydroxyurea
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02042222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02042222.